These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

290 related articles for article (PubMed ID: 18854565)

  • 1. Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases.
    Kesmodel SB; Ellis LM; Lin E; Chang GJ; Abdalla EK; Kopetz S; Vauthey JN; Rodriguez-Bigas MA; Curley SA; Feig BW
    J Clin Oncol; 2008 Nov; 26(32):5254-60. PubMed ID: 18854565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver resection remains a safe procedure after neoadjuvant chemotherapy including bevacizumab: a case-controlled study.
    Tamandl D; Gruenberger B; Klinger M; Herberger B; Kaczirek K; Fleischmann E; Gruenberger T
    Ann Surg; 2010 Jul; 252(1):124-30. PubMed ID: 20562613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of bevacizumab added preoperatively to oxaliplatin on liver injury and complications after resection of colorectal liver metastases.
    van der Pool AE; Marsman HA; Verheij J; Ten Kate FJ; Eggermont AM; Ijzermans JN; Verhoef C
    J Surg Oncol; 2012 Dec; 106(7):892-7. PubMed ID: 22552819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Does neoadjuvant chemotherapy reveal disease precluding surgical treatment of initially resectable colorectal cancer liver metastases?
    Reddy SK; Tsung A; Marsh JW; Geller DA
    J Surg Oncol; 2012 Jan; 105(1):55-9. PubMed ID: 21842519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [The safety of perioperative bevacizumab use].
    Mariani P
    J Chir (Paris); 2010 Jan; 147 Suppl 1():S12-7. PubMed ID: 20172200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lack of evidence for increased operative morbidity after hepatectomy with perioperative use of bevacizumab: a matched case-control study.
    D'Angelica M; Kornprat P; Gonen M; Chung KY; Jarnagin WR; DeMatteo RP; Fong Y; Kemeny N; Blumgart LH; Saltz LB
    Ann Surg Oncol; 2007 Feb; 14(2):759-65. PubMed ID: 17103075
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected liver metastases from colorectal cancer.
    Turan N; Benekli M; Koca D; Ustaalioglu BO; Dane F; Ozdemir N; Ulas A; Oztop I; Gumus M; Ozturk MA; Berk V; Kucukoner M; Uner A; Balakan O; Helvaci K; Ozkan S; Yilmaz U; Buyukberber S;
    Oncology; 2013; 84(1):14-21. PubMed ID: 23076023
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of preoperative targeted therapy on postoperative complications after resection of colorectal liver metastases.
    Neeff HP; Drognitz O; Klock A; Illerhaus G; Opitz OG; Hopt UT; Makowiec F
    Int J Colorectal Dis; 2012 May; 27(5):635-45. PubMed ID: 22139030
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bevacizumab treatment before resection of colorectal liver metastases: safety, recovery of liver function, pathologic assessment.
    Dede K; Mersich T; Besznyák I; Zaránd A; Salamon F; Baranyai ZS; Landherr L; Jakab F; Bursics A
    Pathol Oncol Res; 2013 Jul; 19(3):501-8. PubMed ID: 23420304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases.
    Aloia T; Sebagh M; Plasse M; Karam V; Lévi F; Giacchetti S; Azoulay D; Bismuth H; Castaing D; Adam R
    J Clin Oncol; 2006 Nov; 24(31):4983-90. PubMed ID: 17075116
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preoperative chemotherapy and the risk of hepatotoxicity and morbidity after liver resection for metastatic colorectal cancer: a single institution experience.
    Wolf PS; Park JO; Bao F; Allen PJ; DeMatteo RP; Fong Y; Jarnagin WR; Kingham TP; Gönen M; Kemeny N; Shia J; D'Angelica MI
    J Am Coll Surg; 2013 Jan; 216(1):41-9. PubMed ID: 23041049
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted molecular therapies (cetuximab and bevacizumab) do not induce additional hepatotoxicity: preliminary results of a case-control study.
    Pessaux P; Panaro F; Casnedi S; Zeca I; Marzano E; Bachellier P; Jaeck D; Chenard MP
    Eur J Surg Oncol; 2010 Jun; 36(6):575-82. PubMed ID: 20452168
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of bevacizumab on functional recovery and histology of the liver after resection of colorectal metastases.
    Wicherts DA; de Haas RJ; Sebagh M; Saenz Corrales E; Gorden DL; Lévi F; Paule B; Azoulay D; Castaing D; Adam R
    Br J Surg; 2011 Mar; 98(3):399-407. PubMed ID: 21254017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospective pilot study of neoadjuvant chemotherapy with 5-fluorouracil, folinic acid and oxaliplatin in resectable liver metastases of colorectal cancer. Analysis of 42 neoadjuvant chemotherapies.
    Lorenz M; Staib-Sebler E; Gog C; Proschek D; Jauch KW; Ridwelski K; Hohenberger W; Gassel HJ; Lehmann U; Vestweber KH; Padberg W; Zamzow K; Müller HH
    Zentralbl Chir; 2003 Feb; 128(2):87-94. PubMed ID: 12632273
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response to chemotherapy predicts survival following resection of hepatic colo-rectal metastases in patients treated with neoadjuvant therapy.
    Small RM; Lubezky N; Shmueli E; Figer A; Aderka D; Nakache R; Klausner JM; Ben-Haim M
    J Surg Oncol; 2009 Feb; 99(2):93-8. PubMed ID: 19065637
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab.
    Yoo PS; Lopez-Soler RI; Longo WE; Cha CH
    Clin Colorectal Cancer; 2006 Sep; 6(3):202-7. PubMed ID: 17026789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bevacizumab and postoperative wound complications in patients with liver metastases of colorectal cancer.
    Utsumi H; Honma Y; Nagashima K; Iwasa S; Takashima A; Kato K; Hamaguchi T; Yamada Y; Shimada Y; Kishi Y; Nara S; Esaki M; Shimada K
    Anticancer Res; 2015 Apr; 35(4):2255-61. PubMed ID: 25862887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neoadjuvant and adjuvant therapy in relation to surgery for colorectal liver metastases.
    Brouquet A; Nordlinger B
    Scand J Gastroenterol; 2012 Mar; 47(3):286-95. PubMed ID: 22182353
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Colorectal cancer metastases: surgical indications and multimodal approach.
    Ciferri E; Bondanza GS; Municinò O; Castagnola M; Gazzaniga GM
    Hepatogastroenterology; 2003; 50(54):1836-46. PubMed ID: 14696416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bevacizumab in combination with fluorouracil and leucovorin: an active regimen for first-line metastatic colorectal cancer.
    Hurwitz HI; Fehrenbacher L; Hainsworth JD; Heim W; Berlin J; Holmgren E; Hambleton J; Novotny WF; Kabbinavar F
    J Clin Oncol; 2005 May; 23(15):3502-8. PubMed ID: 15908660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.